Aug-2021 Safety data – mHSPC therapy and CVD risk profile
Speakers: Prof. Axel Merseburger (Lubeck, Germany)
Prof. Merseburger uses data from animal models and basic research to illustrate the effect of ADT in cardiovascular risk, as well as other treatment modalities (chemotherapy, surgery, ADT alone or in combination). In addition, new treatment modalities and CVD toxicity are also highlighted in his talk.
